• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

New Study: Management of Excessive Daytime Sleepiness Associated with Narcolepsy or OSA

February 20, 2021 by admin

Excessive sleepiness is a symptom of narcolepsy and obstructive sleep apnea (OSA). In a recently published study titled “Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives” a trial was performed to determine whether solriamfetol was effective in reducing sleep propensity and maintaining wakefulness in narcolepsy and OSA as well as showing significant reduction in Epworth Sleepiness Scale (ESS) scores and improvements in mean maintenance of wakefulness test (MWT) compared to a placebo.

Solriamfetol is a first-line, FDA approved treatment for drowsiness in narcolepsy and OSA and as a replacement therapy for patients who have had unsuccessful treatment or unacceptable side effects with stimulants, pitolisant, armodafinil, and modafinil. 

It can also be used as an additional therapy for narcolepsy and OAS when excessive sleepiness is partially controlled with certain other sleep medicines, such as stimulants or sodium oxybate, armodafinil, modafinil, and pitolisant.  Solriamfetol is a derivative of phenylalanine. Its ability to combat fatigue is thought to be due to its inhibition of selective dopamine and norepinephrine reuptake. 

 

Test Conclusions

The TONES 2-5 trials showed that solriamfetol is an effective first-line or add-on therapy for narcolepsy or OSA. The drug was determined to promote wakefulness, decrease propensity to sleep, and improve quality of life both in the short and long-term. Solriamfetol also has a good safety profile with minimal side effects. Compared to other options, solriamfetol may be a better option for patients who are taking medications that are metabolized through the cytochrome P450 enzymes (such as hormonal contraceptives) or patients with comorbid liver disease. The patient’s insurance may be another factor that may influence whether the drug is prescribed as a first-line or add-on treatment in narcolepsy or OSA. Continued research in narcolepsy and OSA will help to develop more specific therapies that may change solriamfetol’s role in the treatment of these patients.

 

Click here to read full article

Filed Under: Blog, News Tagged With: narcolepsy

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy